ADX has released its new set of diagnostic assays for Alzheimer's disease, comprising ELISAs for β-amyloid 1-40 and 1-42 and total tau.
Offered through the company's partner Euroimmun, the assays are EU CE marked, automatable, and do not suffer from matrix effects, the company said.